Alendronate affects calcium dynamics in cardiomyocytes in vitro

Vascular Pharmacology

Volumn 51, Issue 5-6, 2009, Pages 350-358

  Kemeny Suss, Naomi ^a   Kasneci, Amanda ^b,c   Rivas, Daniel ^c   Afilalo, Jonathan ^d   Komarova, Svetlana V ^a   Chalifour, Lorraine E ^b,c   Duque, Gustavo ^c,e  

^a MCGILL UNIVERSITY   (Canada)

^b Bank of Montreal Center for the Study of Heart Disease in Women   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Arrhythmia; Atrial fibrillation; Bisphosphonates; Calcium; Cardiomyocytes

Indexed keywords

ALENDRONIC ACID; CAFFEINE; CALCIUM ION;

ACUTE TOXICITY; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARDIOTOXICITY; CELL PROLIFERATION; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG EXPOSURE; HEART ATRIUM; HEART MUSCLE CELL; HEART VENTRICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PRENYLATION;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CAFFEINE; CALCIUM; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MYOCYTES, CARDIAC; PROTEIN PRENYLATION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 70449112646     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.09.002     Document Type: Article

References (56)

1. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 70 (2008) 23-49
2. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (2007) 1809-1822
3. Brundel B.J., Shiroshita-Takeshita A., Qi X., Yeh Y.H., Chartier D., van Gelder I.C., et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ. Res. 99 (2006) 1394-1402
4. Choi B.R., Burton F., and Salama G. Cytosolic Ca2+ triggers early after depolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. J. Physiol. 543 (2002) 615-631
5. Chopra N., Kannankeril P.J., Yang T., Hlaing T., Holinstat I., Ettensohn K., et al. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice. Circ. Res. 101 (2007) 617-626
6. Claycomb W.C., Lanson Jr. N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2979-2984
7. Cummings S.R., Schwartz A.V., and Black D.M. Alendronate and atrial fibrillation. N. Engl. J. Med. 356 (2007) 1895-1896
8. De Koninck P., and Schulman H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science 279 (1998) 227-230
9. Desantiago J., Ai X., Islam M., Acuna G., Ziolo M.T., Bers D.M., et al. Arrhythmogenic effects of beta2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ. Res. 102 (2008) 1389-1397
10. di Barletta M.R., Viatchenko-Karpinski S., Nori A., Memmi M., Terentyev D., Turcato F., et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 114 (2006) 1012-1019
11. Diel I.J., Bergner R., and Grotz K.A. Adverse effects of bisphosphonates: current issues. J. Support. Oncol. 5 (2007) 475-482
12. Dolmetsch R.E., Xu K., and Lewis R.S. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392 (1998) 933-936
13. Duque G., El Abdaimi K., Macoritto M., Miller M.M., and Kremer R. Estrogens (E2) regulate expression and response of 1, 25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation. Biochem. Biophys. Res. Commun. 299 (2002) 446-454
14. Fahrenbach J.P., Mejia-Alvarez R., and Banach K. The relevance of non-excitable cells for cardiac pacemaker function. J. Physiol. 585 (2007) 565-578
15. Gu X., and Spitzer N.C. Distinct aspects of neuronal differentiation encoded by frequency of spontaneous Ca2+ transients. Nature 375 (1995) 784-787
16. Heckbert S.R., Li G., Cummings S.R., Smith N.L., and Psaty B.M. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med. 168 (2008) 826-831
17. Hescheler J., Meyer R., Plant S., Krautwurst D., Rosenthal W., and Schultz G. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ. Res. 69 (1991) 1476-1486
18. Hewitt R.E., Lissina A., Green A.E., Slay E.S., Price D.A., and Sewell A.K. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol. 139 (2005) 101-111
19. Keller R.K., and Fliesler S.J. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem. Biophys. Res. Commun. 266 (1999) 560-563
20. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J. Dent. Res. 86 (2007) 1022-1033
21. Knollmann B.C., and Roden D.M. A genetic framework for improving arrhythmia therapy. Nature 451 (2008) 929-936
22. Knollmann B.C., Chopra N., Hlaing T., Akin B., Yang T., Ettensohn K., et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J. Clin. Invest. 116 (2006) 2510-2520
23. Komarova S.V., Pereverzev A., Shum J.W., Sims S.M., and Dixon S.J. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2643-2648
24. Kubalova Z., Gyorke I., Terentyeva R., Viatchenko-Karpinski S., Terentyev D., Williams S.C., et al. Modulation of cytosolic and intra-sarcoplasmic reticulum calcium waves by calsequestrin in rat cardiac myocytes. J. Physiol. 561 (2004) 515-524
25. Lahat H., Eldar M., Levy-Nissenbaum E., Bahan T., Friedman E., Khoury A., et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 103 (2001) 2822-2827
26. Lakireddy V., Baweja P., Syed A., Bub G., Boutjdir M., and El-Sherif N. Contrasting effects of ischemia on the kinetics of membrane voltage and intracellular calcium transient underlie electrical alternans. Am. J. Physiol., Heart Circ. Physiol. 288 (2005) H400-H407
27. Lane J.M., Serota A.C., and Raphael B. Osteoporosis: differences and similarities in male and female patients. Orthop. Clin. North Am. 37 (2006) 601-609
28. Li W., Llopis J., Whitney M., Zlokarnik G., and Tsien R.Y. Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression. Nature 392 (1998) 936-941
29. Liang P.H., Ko T.P., and Wang A.H. Structure, mechanism and function of prenyltransferases. Eur. J. Biochem. 269 (2002) 3339-3354
30. Liu J., Noble P.J., Xiao G., Abdelrahman M., Dobrzynski H., Boyett M.R., et al. Role of pacemaking current in cardiac nodes: insights from a comparative study of sinoatrial node and atrioventricular node. Prog. Biophys. Mol. Biol. 96 (2008) 294-304
31. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13 (1998) 581-589
32. Menard C., Pupier S., Mornet D., Kitzmann M., Nargeot J., and Lory P. Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells. J. Biol. Chem. 274 (1999) 29063-29070
33. Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., Krause K.H., et al. Calreticulin is essential for cardiac development. J. Cell Biol. 144 (1999) 857-868
34. Nakamura K., Robertson M., Liu G., Dickie P., Nakamura K., Guo J.Q., et al. Complete heart block and sudden death in mice overexpressing calreticulin. J. Clin. Invest. 107 (2001) 1245-1253
35. Ogawa Y., Kurebayashi N., and Murayama T. Ryanodine receptor isoforms in excitation-contraction coupling. Adv. Biophys. 36 (1999) 27-64
36. Porras A.G., Holland S.D., and Gertz B.J. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36 (1999) 315-328
37. Postma A.V., Denjoy I., Hoorntje T.M., Lupoglazoff J.M., Da Costa A., Sebillon P., et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 91 (2002) e21-e26
38. Priori S.G., Napolitano C., Memmi M., Colombi B., Drago F., Gasparini M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106 (2002) 69-74
39. Rauch F., Prud'homme J., Arabian A., Dedhar S., and St-Arnaud R. Heart, brain, and body wall defects in mice lacking calreticulin. Exp. Cell Res. 256 (2000) 105-211
40. Reszka A.A., and Rodan G.A. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev. Med. Chem. 4 (2004) 711-719
41. Salama G. Arrhythmia genesis: aberrations of voltage or Ca2+ cycling?. Heart Rhythm 3 (2006) 67-70
42. Sartiani L., Bochet P., Cerbai E., Mugelli A., and Fischmeister R. Functional expression of the hyperpolarization-activated, non-selective cation current I(f) in immortalized HL-1 cardiomyocytes. J. Physiol. 545 (2002) 81-92
43. Sipido K.R., and Marban E. L-type calcium channels, potassium channels, and novel nonspecific cation channels in a clonal muscle cell line derived from embryonic rat ventricle. Circ. Res. 69 (1991) 1487-1499
44. Sorensen H.T., Christensen S., Mehnert F., Pedersen L., Chapurlat R.D., Cummings S.R., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336 (2008) 813-816
45. Steinberg S.F., Alcott S., Pak E., Hu D., Protas L., Moise N.S., et al. Beta(1)-receptors increase cAMP and induce abnormal Ca(i) cycling in the German shepherd sudden death model. Am. J. Physiol., Heart Circ. Physiol. 282 (2002) H1181-H1188
46. Stepensky D., Golomb G., and Hoffman A. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J. Pharm. Sci. 91 (2002) 508-516
47. Swynghedauw B., Chevalier B., Charlemagne D., Mansier P., and Carre F. Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Cardiovasc. Res. 35 (1997) 6-12
48. Tsai C.T., Wang D.L., Chen W.P., Hwang J.J., Hsieh C.S., Hsu K.L., et al. Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes. Circ. Res. 100 (2007) 1476-1485
49. Uhlen P. Spectral analysis of calcium oscillations. Sci. STKE 2004 (2004) l15
50. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264 (1999) 108-111
51. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. 255 (1999) 491-494
52. Vest J.A., Wehrens X.H., Reiken S.R., Lehnart S.E., Dobrev D., Chandra P., et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111 (2005) 2025-2032
53. White S.M., Constantin P.E., and Claycomb W.C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol., Heart Circ. Physiol. 286 (2004) H823-H829
54. Yeh, Y.H., W.R., Qi, X., Chartier, D., Boknik, P., Kaab, S., Ravens, U., et al., 2008. Calcium handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. CIRCEP Online 30 April 2008.
55. Yun M.H., Woo J.S., and Kwon K.I. Bioequivalence and pharmacokinetics of 70 mg alendronate sodium tablets by measuring alendronate in plasma. Arch. Pharm. Res. 29 (2006) 328-332
56. Zizic T.M. Pharmacologic prevention of osteoporotic fractures. Am. Fam. Phys. 70 (2004) 1293-1300